Abstract
Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of combination strategies with conventional antitumor agents.
| Original language | English |
|---|---|
| Pages (from-to) | 856-868 |
| Number of pages | 13 |
| Journal | Mini-Reviews in Medicinal Chemistry |
| Volume | 8 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2008 |
Fingerprint
Keywords
- Apoptosis
- Cancer cells
- Drug combination
- Histone deacetylase inhibitors
- Nutlins
- p53
- Pifithrins
- Ubiquitin ligase inhibitors
ASJC Scopus subject areas
- Medicine (miscellaneous)
- Chemistry(all)
- Pharmacology
Cite this
Small molecules targeting p53 to improve antitumor therapy. / Beretta, Giovanni L.; Gatti, L.; Benedetti, V.; Perego, P.; Zunino, F.
In: Mini-Reviews in Medicinal Chemistry, Vol. 8, No. 9, 2008, p. 856-868.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Small molecules targeting p53 to improve antitumor therapy
AU - Beretta, Giovanni L.
AU - Gatti, L.
AU - Benedetti, V.
AU - Perego, P.
AU - Zunino, F.
PY - 2008
Y1 - 2008
N2 - Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of combination strategies with conventional antitumor agents.
AB - Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of combination strategies with conventional antitumor agents.
KW - Apoptosis
KW - Cancer cells
KW - Drug combination
KW - Histone deacetylase inhibitors
KW - Nutlins
KW - p53
KW - Pifithrins
KW - Ubiquitin ligase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=50149118399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=50149118399&partnerID=8YFLogxK
U2 - 10.2174/138955708785132774
DO - 10.2174/138955708785132774
M3 - Article
C2 - 18691143
AN - SCOPUS:50149118399
VL - 8
SP - 856
EP - 868
JO - Mini-Reviews in Medicinal Chemistry
JF - Mini-Reviews in Medicinal Chemistry
SN - 1389-5575
IS - 9
ER -